Abstract:
HAART has been extremely successful in
suppressing HIV infection, restoring im-
mune function, and improving health,
and it has led to dramatic decreases in
morbidity and mortality in those areas of
the developing world where HIV infection
is most prevalent. Studies from the ART
in Lower Income Countries cohort and
from Malawi, Uganda, Cote de’Ivoire, and
India have clearly demonstrated that
1 75% of HIV-infected individuals who re-
ceive fixed-dose combination (FDC) ther-
apy with a nonnucleoside reverse-tran-
scriptase inhibitor have excellent viral
suppression [1–5]. These successes have
been outstanding and have driven the
scale-up of HAART as a global health
priority. More than 2 million individuals
in the developing world are receiving
HAART; most of these individuals are in
sub-Saharan Africa, which bears the brunt
of the HIV epidemic.
The successful development of HIV
care programs to deliver HAART faces
